Recombinant MTAP antibody (AA 97-196)

Catalog No. ABIN7877261

This Mouse Monoclonal antibody specifically detects MTAP in WB and IHC (p). It exhibits reactivity toward Human.

Quick Overview for Recombinant MTAP antibody (AA 97-196) (ABIN7877261)

Target: MTAP (Methylthioadenosine phosphorylase (MTAP))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This MTAP antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: RMTAP-1813

Product Details anti-MTAP Antibody

Binding Specificity: AA 97-196

Purpose: Recombinant MTAP Antibody / S-methyl-5'-thioadenosine phosphorylase (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogen: A recombinant human partial protein (amino acids 97-196) was used as the immunogen for this MTAP antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the recombinant MTAP antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the recombinant MTAP antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for MTAP

Target: MTAP (Methylthioadenosine phosphorylase (MTAP))

Alternative Name: MTAP

Background: Recognizes a protein of 31 kDa, which is identified as MTAP (5'-deoxy-5'-methylthioadenosine phosphorylase). It catalyzes the reversible phosphorolysis of methylthioadenosine, which is important in polyamine metabolism and for the salvage of adenine and methionine. The gene encoding MTAP is linked to the tumor suppressor gene, p16INK4A. Deficient levels of MTAP can occur in cancers primarily through co-deletion of the MTAP gene and the p16INK4A gene. Cells expressing MTAP and possessing adenine salvage pathway activity may be less susceptible to malignancy due to growth-inhibitory actions of agents (e.g. antifolates), whose mechanism of action, in part, involves this de novo purine pathway.

UniProt: Q13126

Pathways: Ribonucleoside Biosynthetic Process, Methionine Biosynthetic Process